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Figure 1.
Page 2 of 18
https://mc.manuscriptcentral.com/bjo
British Journal of Ophthalmology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Low-dose (0.01%) atropine eye drops to reduce progression of myopia in 
children: a multi-centre placebo-controlled randomised trial in the United 
Kingdom (CHAMP-UK) – study protocol.  
Augusto Azuara-Blanco (Centre for Public Health, Queen’s University Belfast, Belfast, UK)
Nicola Logan (Optometry School, Aston University, Birmingham, UK)
Niall Strang (Optometry School, Glasgow Caledonian University, Glasgow, UK)
Kathryn Saunders (Optometry School, Ulster University, Coleraine, UK)
Peter Allen (Optometry School, Anglia Ruskin University, Cambridge, UK)
Ruth Weir (Northern Ireland Clinical Trials Unit, Belfast, UK)
Paul Doherty (Northern Ireland Clinical Trials Unit, Belfast, UK)
Catherine Adams (Northern Ireland Clinical Trials Unit, Belfast, UK)
Evie Gardner (Northern Ireland Clinical Trials Unit, Belfast, UK)
Ruth E Hogg (Centre for Public Health, Queen’s University Belfast, Belfast, UK))
Margaret McFarland (Department of Pharmacy, Belfast Health and Social Care Trust, Belfast, 
UK)
Jennifer Preston (Institute of Translational Medicine, University of Liverpool, Liverpool, UK)
Rejina Verghis (Northern Ireland Clinical Trials Unit, Belfast, UK)
James Loughman (Optometry School, Technological University Dublin, Dublin, Ireland)
Ian Flitcroft (Optometry School, Technological University Dublin, Dublin, Ireland)
David Mackey (Lions Eye Institute, University of Western Australia, Perth, Australia)
Samantha Lee (Lions Eye Institute, University of Western Australia, Perth, Australia)
Chris Hammond (St Thomas’ Eye Hospital, King’s College London, London, UK)
Nathan Congdon (Centre for Public Health, Queen’s University Belfast, Belfast, UK; Orbis 
International, New York, USA; and Zhongshan Ophthalmic Centre, Sun Yat-sen University, 
Guangzhou, China)
Mike Clarke (Centre for Public Health, Queen’s University Belfast, Belfast, UK and Northern 
Ireland Clinical Trials Unit, Belfast, UK)
Corresponding Author:  Augusto Azuara-Blanco, PhD, FRCS(Ed), FRCOphth
Centre for Public Health, Institute of Clinical Sciences - Block A, Grosvenor Road, Belfast BT12 6BA.  
Ph:  02890976460. E-mail: a.azuara-blanco@qub.ac.uk  
Word count: 2997
Acronym: The Childhood Atropine for Myopia Progression in the UK study (CHAMP-UK)  
Trial registration: ISRCTN99883695, NCT03690089.
Page 3 of 18
https://mc.manuscriptcentral.com/bjo
British Journal of Ophthalmology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Precis
We report the protocol of a multicentre placebo-controlled randomised trial that will evaluate the 
efficacy, safety and mechanism of action of low dose atropine (0.01%) eye drops to reduce myopia 
progression in children with myopia.
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Abstract
Background/Aims:  To report the protocol of a trial designed to evaluate the efficacy, safety and 
mechanism of action of low dose atropine (0.01%) eye drops for reducing progression of myopia in 
UK children.
Methods:  Multicentre, double-masked, superiority, placebo-controlled, randomised trial.  We will 
enrol children aged 6-12 years with myopia of -0.50 diopters or worse in both eyes.
We will recruit 289 participants with an allocation ratio of 2:1 (193 atropine; 96 placebo) from five 
centres.  Participants will instil one drop in each eye every day for two years and attend a research 
centre every six months.  The vehicle and preservative will be the same in both study arms.
The primary outcome is spherical equivalent refractive error of both eyes measured by autorefractor 
under cycloplegia at two years (adjusted for baseline).  Secondary outcomes include axial length, 
best corrected distance visual acuity, near visual acuity, reading speed, pupil diameter, 
accommodation, adverse event rates and allergic reactions, quality of life (EQ-5D-Y), and tolerability 
at two years. Mechanistic evaluations will include: peripheral axial length, peripheral retinal defocus, 
anterior chamber depth, iris colour, height and weight, activities questionnaire, ciliary body 
biometry and chorio-retinal thickness.  Endpoints from both eyes will be pooled in combined analysis 
using generalised estimating equations to allow for the correlation between eyes within participant.  
Three years after cessation of treatment, we will also evaluate refractive error and adverse events.
Conclusions: CHAMP-UK will be the first randomised trial reporting outcomes of low-dose atropine 
eye drops for children with myopia in a UK population.  
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Introduction 
In Europe, myopia prevalence has risen dramatically over the last few decades. [1-6]  Myopia 
appears to be occurring at a younger age and its severity has increased by an average of 
approximately 1 dioptre (D) among European-derived populations in one generation. [4, 7]  In UK 
the proportion of myopic children has doubled in the last 50 years.[6]  In the USA myopia 
prevalence increased from 25% to 42% in a generation.[7]
In the UK, most people with myopia have normal visual acuity when appropriately corrected, but 
myopia still has significant public health consequences from a variety of perspectives, educational, 
financial and psychological, as well as the risks of visual impairment. [8-10] Myopia is a risk factor 
for myopic maculopathy, retinal detachment, cataract and glaucoma in adult life, [9, 11, 12] and 
the risk increases with the degree of myopia.  All these conditions are more challenging to treat 
than myopia itself, and reducing the risk for any of them requires interventions to slow myopia 
progression and thus decrease a child’s severity of myopia in the long term rather than correct it 
optically with spectacles. Children with myopia also require frequent eye tests and change of 
spectacles that are funded primarily by taxpayers in the UK.  Strategies to control progression of 
myopia are particularly meaningful in the context of World Health Organisation (WHO) initiatives 
to eliminate preventable causes of blindness. 
Atropine at low concentration has been shown to be safe and effective in slowing myopia 
progression in children of Chinese ethnicity, [13-17] but its safety and effectiveness in European-
derived populations has not been adequately assessed in a controlled trial.  Therefore, the 
objective of the current study is to evaluate the efficacy, safety, and mechanism of action of low 
dose atropine (0.01%) in UK children with myopia.   This paper describes the protocol of the 
randomised controlled trial called CHAMP-UK (The Childhood Atropine for Myopia Progression in 
the UK study).
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Materials and methods
This is a multicentre, randomised, double-masked, placebo-controlled, superiority trial, with 2:1 
allocation of intervention and control (atropine:placebo).
Participants: Children will be eligible to participate in the study if they are 6-12 years of age at the 
time of consent, with myopia of -0.50 D or greater (spherical equivalent refractive error) in both 
eyes, best-corrected distance visual acuity (BCDVA) 0.20 logMAR or better in both eyes, and no other 
significant ocular or systemic morbidities (see Table 1).  Children with myopia ≥ -10.00 D or 
astigmatism ≥ 2.00 D in either eye will be excluded. 
------------------------------------------------------------------------------------------------------------------------------------- 
Table 1:  Inclusion and Exclusion Criteria:
Inclusion Criteria1. 6-12 years of age (at the time of consenting) 2. Myopia of -0.5D or greater (spherical equivalent refractive error) in both eyes 3. Best-corrected distance visual acuity (BCDVA) 0.20 logMAR or better in both eyes
Exclusion Criteria1. Children with other ocular morbidities*2. Myopia of -10D or greater in either eye 3. Astigmatism of 2D or higher in either eye4. Amblyopia5. Significant health problems that can compromise the ability to attend research visits or 
complete the trial6. Other factors that may compromise the ability to attend the research appointments7. Parents or children with poor understanding of the English language 8. Children enrolled in other interventional trials9. Allergy or hypersensitivity to atropine or excipients 10. Prior or current use of atropine or orthokeratology contact lenses
-------------------------------------------------------------------------------------------------------------------------------------
* Ocular co-morbidities refer to any disease that can potentially compromised vision or that may 
require ocular surgery, including diabetes mellitus.
Setting: Clinical research facilities from the following five academic departments of medical or 
optometry schools and NHS Trusts in Northern Ireland, England and Scotland:
- Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility (NICRF): Belfast Health and 
Social Care Trust, Queen’s University Belfast and Ulster University, Northern Ireland 
- Department of Optometry at Glasgow Caledonian University and NHS Greater Glasgow and Clyde, 
Scotland
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- School of Optometry at Aston University and Birmingham Women and Children's NHS Foundation 
Trust, England
- Department of Vision and Hearing Sciences at Anglia Ruskin University and Cambridge University 
Hospitals NHS Hospital Trust, England
- Moorfields Eye Hospital NHS Foundation Trust, England
Study Interventions: The intervention group will receive preserved 0.01% atropine sulfate eye drops, 
administered at home once daily in both eyes for two years. The control group will receive placebo 
eye drops on the same dosing schedule, with the same preservative (benzalkonium chloride 0.01% 
w/v in sterile water) and pH.  Atropine and placebo bottles will be identical, and thus participants 
and investigators will be masked to study group assignment. 
Outcomes: The primary outcome is spherical equivalent refractive error (SER) (i.e. myopia severity) 
of both eyes after 24 months measured by autorefractor under cycloplegia, adjusted for baseline.  
Participants will have 1-2 drops of 1% cyclopentolate HCl instilled in each eye at least 20 minutes 
before autorefraction and another drop will be instilled if full cycloplegia has not been achieved.  
The autorefractor derives an average of five readings to produce the SER. The spherical equivalent 
refractive error (i.e, the spherical power plus half the cylindrical power) will be recorded for each 
eye. 
Secondary outcomes of both eyes include the following: axial length (measured with partial coherent 
interferometry), best corrected distance visual acuity (uniocular and binocular), uniocular and 
binocular near visual acuity (ETDRS), reading speed (Wilkins), pupil diameter (by autorefractometer), 
accommodation (using a near target), spectacle correction power, adverse event rates and allergic 
reactions, quality of life (EQ-5D-Y),[18] and tolerability at two years.  
The mechanism through which atropine inhibits myopia remains uncertain. Possible sites of action 
include the lens and ciliary muscle, the sclera, choroid and the retina. [11] A variety of tests will be 
done, according to their availability in the research units, to explore the effect of atropine on ocular 
anatomy and function. In experimental models, atropine reduces myopia and ocular elongation via a 
non-accommodative mechanism. [19]  However, an accommodative effect cannot be ruled out in 
humans. [20]  We will study the effect of atropine on the lens and ciliary muscle by measuring the 
anterior chamber depth with laser biometry and assessing changes in ciliary muscle using anterior-
segment optical coherence tomography (OCT). 
Altering the amount of defocus in the peripheral retina appears to be one mechanism influencing 
growth rate of the eye in myopia progression. [21]  Whether topical atropine also has some 
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influence in the peripheral retina is unknown. Changes in peripheral eye length and off-axis 
measures of refraction are two ways in which the peripheral properties of the eye can be assessed. 
In the posterior eye, subfoveal choroid thinning is correlated with the degree of myopia. Changes in 
subfoveal choroidal thickness may occur in response to imposed retinal defocus. [22-24]  We will 
study choroidal thickness using OCT.  This will enable differences in choroidal thickness resulting 
from atropine use to be compared with normal myopic growth. We will also explore the influence of 
parental myopia using parents’ current spectacle prescription power, and time spent on outdoor and 
indoor activities (Table 2).
   Table 2.   Diary used to record time spent indoor or outdoor.
Activity, to nearest 
whole hour
Monday Tuesday Wednesday Thursday Friday Saturday SundayHours indoors: classroom, music etcHours outside: sport, training, walking / cycling to or from school Hours reading, homework, video / computer / tablet / mobile phone useHours outside: sport, training, walking / cycling to or from school 
Compliance will be assessed using electronic monitoring with a MEMS device (AARDEX Group Ltd, 
Switzerland).  The MEMS Cap is a plastic container with a screw top in which the eye drop bottle is 
stored until needed for drop instillation. [25]  When the top is unscrewed the device electronically 
records the date and time, and this is downloaded, analysed and taken as a surrogate for having 
administered the medication.
At five years after randomisation, we will post a questionnaire to participants’ parents and ask for 
details of any possible complications and adverse events after trial completion. We will also request 
information from their children’s optometrists regarding their eye health, visual acuity, and 
refractive error data.
Sample size: We anticipate that the underlying progression in the control group and the effect of 
atropine eye drops in a UK population will be smaller than the reported effect in Chinese 
populations, [17] but assuming that atropine reduces the progression of myopia by at least 40%, 
using SD=0.7, an intra-class correlation coeficient between the two eyes of 0.9 and a variation 
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inflation factor of 1.9, we will need 97 participants in each group. Considering a dropout rate of 15% 
and that 10% of recruited children will be Chinese, we will need a total of 289 participants: 193 
atropine, 96 placebo (152 atropine, 76 placebo inflated by a variance inflation factor of 1.9) to detect 
this difference in the non-Chinese UK population with 90% power.
Allocation: Randomisation will be computer-generated using a minimisation algorithm to ensure 
balanced allocation of participants across the two treatment groups, and that each participant’s 
allocation is fully concealed from everyone involved in recruiting them to the trial.  Minimisation will 
be by centre, ethnic background (white/non-white), and severity of myopia (less than -3.00 D in 
either eye / -3.00 D or greater in the eye with more severe myopia). The unit of randomisation will 
be the participant (not the eye).  The randomisation list will be generated by sealed envelope 
(sealedenvelope.com) and group allocation will only be visible to those with administrator access in 
the trial management team in NICTU. Local researchers will access the automated randomisation 
system to obtain the kit number for each participant.
Adverse events/Safety reporting: Serious adverse events (SAEs) related to participants’ participation 
in the trial are reported in accordance with the guidance from The European Clinical Trials Directive 
2001/20/EC  (https://ec.europa.eu/health/human-use/clinical-trials/directive_en). 
Timeline of procedures: Table 3 displays the timing of the trial’s outcome measurements.  
Participants will attend a research centre every six months (+/- two weeks) across the 2-year follow-
up as illustrated in Figure 1 (see Table 3 for details).  Following completion of the 2-year trial, 
participants will then again be contacted at the 5-year time point (three years after cessation of eye 
drops) to evaluate their refractive error and possible adverse events.
Recruitment strategy: We will ask community optometrists and paediatric ophthalmologists to 
inform parents of children with myopia about the trial.  We will aim to recruit approximately 60 
participants per centre.  
Data collection:  The chief investigator (CI) and NICTU will provide training to site staff on trial 
processes and procedures, including the completion of the clinical research form (CRF) and data 
collection through investigator meetings and site initiation visits.  All data for an individual 
participant will be collected by the local principal investigator (PI) or designee and recorded in the 
CRF for the study. Participant identification on the CRF will be through their unique trial identifier, 
allocated at the time of recruitment. Data will be collected and recorded on the CRF and 
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questionnaires by the local PI or designee.  Case report forms and questionnaires will be submitted 
to the NICTU in a timely manner.
Data management: Study data will be entered onto a web-based Clinical Trial Database and 
processed electronically as per NICTU standard operating procedures and the study specific data 
management plan. Data queries will be generated for site staff as required to clarify data or request 
missing information. All queries will be responded to and resolved within the study database. Any 
amended information will then be entered in the study database. All study documentation (including 
participant medical records) and data will be archived as per regulatory requirements and those 
responsible for archiving will be noted on the sponsor delegation framework. 
Statistical analysis:  The primary analysis will be performed based on the intention to treat principle.  
A p-value <0.05 is considered as statistically significant. Baseline characteristics will be summarised 
as mean and standard deviation (SD), median and inter-quartile range (IQR) or numbers and 
proportions (%) as appropriate, depending on the scale of measurement and distribution.  
Endpoints from both eyes will be pooled in combined analysis using generalised estimating 
equations to allow for the correlation between eyes within participant.  Difference in the myopia 
progression and other continuous outcomes between the atropine and control groups will also be 
tested for significance using independent t-test. Analysis of covariance will be performed to adjust 
for baseline characteristics and other covariates. Fisher’s exact test will be used to test the 
difference in the proportions between the groups for the categorical variables. Exploratory subgroup 
analyses will be performed on the primary outcome using 99% confidence intervals and interaction 
terms (treatment group by subgroup) for the following subgroups: age (6-9 and 10-12 years at 
randomisation), ethnic background (white versus non-white), and severity of myopia (less than -3D 
in either eye versus -3D or greater myopia). Sensitivity analyses will assess the impact of missing 
data for the primary outcome by imputing extreme values (lowest and highest). A detailed Statistical 
Analysis Plan, including exploratory analyses, will be completed before the final analysis is started.  
Monitoring:  On-site monitoring will be an on-going activity from the time of initiation until trial 
closeout and will comply with the principles of Good Clinical Practice (GCP).  On-site monitoring visits 
during the trial will check the accuracy of entries on CRFs against the source documents, the 
adherence to the protocol, study procedures and GCP. The local PI or designee will ensure that 
access to all trial related documents including source documents (to confirm their consistency with 
CRF entries) are available during monitoring visits. The extent of source data verification will be 
documented in the monitoring plan.
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Ethics and governance: The trial will comply with the principles of GCP, the requirements and 
standards set out by the EU Directive 2001/20/EC and the applicable regulatory requirements in the 
UK, the Medicines for Human Use (Clinical Trials) Regulations 2004 and subsequent amendments 
and the UK Policy Framework for Health and Social Care Research. CHAMP-UK has been reviewed 
and approved by a Research Ethics Committee (18/NI/0164).  Local NHS Research and Development 
(R&D) approvals will be obtained prior to commencing the trial at the participating sites. An 
independent data and safety monitoring committee will oversee the trial.  A Clinical Trial 
Authorisation was obtained from the Medicines for Human Use Regulatory Authority (MHRA) before 
the start of the trial.
Protocol Compliance: A protocol deviation is defined as an incident that deviates from the normal 
expectation of a particular part of the trial process. Any deviations from the protocol will be fully 
documented on the protocol deviation form in the CRF.
A serious breach is defined as a deviation from the trial protocol or GCP which is likely to effect to a 
significant degree:
(a) The safety or physical or mental integrity of the subjects of the trial; or
(b) The scientific value of the trial
Protocol compliance will be monitored by the NICTU.
Protocol Amendments: Changes to the protocol will require regulatory authority/ethics committee 
approval/favourable opinion prior to implementation. 
Participant Confidentiality: All study reports and communication regarding the study will identify the 
participants by the assigned unique trial identifier only. Computers where information will be stored 
will be password-protected. Participant confidentiality will be maintained at every stage and 
identifying data will not be made publicly available to the extent permitted by the applicable laws 
and regulations. 
Post-trial Care: Administration of study eye drops will stop after 24 months of trial participation. At 
the end of the trial, participants’ myopia will be managed in accordance with standard clinical 
practice.
Dissemination Policy: The final study data report will be provided by the Trial Statistician. It is 
anticipated that the study findings will be published in peer reviewed journals and these articles will 
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be led by the CI. The CI will secure a searchable compendium of these publications and make the 
results readily accessible to the public and healthcare professionals. In addition, study findings may 
be presented at both national and international meetings and to appropriate patient groups.
Data Sharing Statement: Requests for data sharing will be reviewed on a case by case basis by the 
CI and Trial Management Group.  We will share trial data with the CI of the MOSAIC trial 
(ISRCTN36732601) and the WA ATOM trial (ACTRN12617000598381) to facilitate prospective 
individual participant data meta-analysis once the results of the CHAMP-UK trial are accepted for 
publication.   MOSAIC and WA-ATOM are placebo-controlled trials evaluating 0.01% atropine eye 
drops.   WA-ATOM will enrol 150 children aged 6-16 years with progressive myopia.  MOSAIC will 
enrol 250 children aged 6-16 years with progressive myopia (phase 1).  All participants initially 
assigned to the placebo (n=83) crossover to the intervention arm of the study for Phase 2, and 
from month 24 to 36, instil 0.01% atropine eye drops in both eyes once nightly.
Funder: The trial is funded by a grant awarded by NIHR Efficacy and Mechanism Evaluation (project 
15/48/59).  CHAMP-UK is registered (ISRCTN99883695, NCT03690089). The Belfast Health and Social 
Care Trust sponsors the trial and provides the necessary trial insurance. 
Discussion
Myopia typically starts to develop in childhood and although the vision can be corrected with 
glasses, contact lenses or surgery, myopic eyes have an increased risk of developing co-morbidities 
such as glaucoma, cataract, retinal detachment, and choroidal neovascularisation at the macula. [9, 
11]  Importantly, the risks of associated co-morbidity and visual loss are associated with the degree 
of myopia, and cannot be reduced with optical correction alone. Myopia is more prevalent in East 
Asia.  Recent epidemiological studies show increasing rates among adolescents in European 
populations and suggest myopia is occurring at an earlier age than in previous generations. [3-5]  
Myopia usually progresses faster at younger ages, but myopia onset, progression, and stabilisation 
vary widely among individuals and are influenced by a range of variables including environment, 
lifestyle, parental refractive history and ethnicity. [4, 26]    
A number of interventions to reduce the progression of myopia have been investigated. Multifocal 
lenses and under-correction of myopic refractive error have at best a weak effect on myopia 
correction.  While orthokeratology and peripheral defocus contact lenses may have some effect on 
axial length progression, atropine, even at low doses, appears to be the most effective intervention 
in Asian children to reduce progression of myopic refractive error. [27,28]  Low dose atropine is now 
widely used in some East Asian countries for treating children with myopia, but has not been tested 
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in European populations.  
Atropine is an anti-cholinergic agent that is relatively selective for muscarinic receptors. Topical use 
of high-concentration atropine (0.5 to 1.0%) causes pupil dilatation by blocking the muscarinic 
receptors in the pupillary sphincter musculature and reduces or paralyses contraction of the ciliary 
muscle. Both of these result in adverse effects, e.g., photophobia and blurred near (reading) vision 
that are highly undesirable in a school-age population.  Additionally, cessation of topical high-
concentration atropine for myopia control has been associated with rapid myopia progression 
towards original, un-treated levels (“myopia rebound”). [15]  
The effectiveness of low dose atropine (three different concentrations) in children of Chinese race 
has been evaluated. [13-16]  The lowest tested dose of 0.01% was associated with better tolerability 
and efficacy, with minimum rebound effect. [14]  A systematic review and network meta-analysis 
has confirmed muscarinic antagonists as the most effective interventions for myopia control in 
children of Chinese ethnicity. [27]  However, there is limited evidence from European populations on 
atropine effectiveness in controlling myopia progression.  We will also evaluate the possible 
mechanisms of action of atropine, and gather information regarding central and peripheral axial 
length, accommodation, lens position, ciliary body biometry, chorio-retinal thickness and daily 
activities.  
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Legends
Figure 1: Study flow chart with outcome timeline.
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Table 3. Schedule of Assessments
Baseline 6 months 12 months 18 months 24 months
Adverse events    
Tolerability    
EQ-5D-Y questionnaire     
Activities questionnaire- to be sent home with participant for completion     
Best corrected VA (logMAR ETDRS)     
Near VA (near logMAR ETDRS)     
Iris colour 
Reading speed (Wilkins Rate of Reading Test)     
Pupil diameter prior to cycloplegia (autorefractor)     
Accommodation (autorefractor)     
Peripheral retinal defocus (autorefractor)   
Anterior chamber depth (laser biometer)     
Cycloplegic refractive error (autorefractor)     
Ciliary body biometry (AS-OCT)*   
Central axial length (laser biometer)     
Peripheral axial length (laser biometer)   
Chorio-retinal thickness (SD-OCT)     
*: if instrumentation is available
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